Follistatin and the Breast Implant Capsule

BACKGROUND: Breast capsular contracture remains an elusive problem faced by plastic surgeons and is the leading long-term complication after breast implantation. Follistatin (Fst) is a protein with known anti-inflammatory and antifibrotic properties and has the potential to limit the severity of dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Frenkiel, Brett A., Temple-Smith, Peter, de Kretser, David, Southwick, Graeme J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404443/
https://www.ncbi.nlm.nih.gov/pubmed/28458972
http://dx.doi.org/10.1097/GOX.0000000000001258
_version_ 1783231597312475136
author Frenkiel, Brett A.
Temple-Smith, Peter
de Kretser, David
Southwick, Graeme J.
author_facet Frenkiel, Brett A.
Temple-Smith, Peter
de Kretser, David
Southwick, Graeme J.
author_sort Frenkiel, Brett A.
collection PubMed
description BACKGROUND: Breast capsular contracture remains an elusive problem faced by plastic surgeons and is the leading long-term complication after breast implantation. Follistatin (Fst) is a protein with known anti-inflammatory and antifibrotic properties and has the potential to limit the severity of diseases associated with inflammation and fibrosis such as capsular contracture. The aim of this study was to examine the effect of Fst288 on capsular fibrosis around silicone implants in a mouse model. METHODS: BALB/c mice were implanted subcutaneously with untreated silicone implants (baseline control). In the experimental group, immediately after silicone implant insertion, the implant pocket received either a single injection of 1 µg Fst288 or normal saline (internal control). The animals were killed at 3, 5, 7, 14, 28, and 90 days after surgery, and serum, implants, and the surrounding tissue were removed for histological and immunohistochemical analyses. RESULTS: Fst288 treatment resulted in significant decreases in capsule thickness at 28 days (P < 0.05) and 3 months (P < 0.001), decreased collagen production at 14 days (P < 0.05) and 3 months (P < 0.01), decreased angiogenesis at 3 months (P < 0.001), decreased α-smooth muscle actin levels at 3 months (P < 0.05), and a decrease in the number of CD45+ cells at days 5 (P < 0.05) and 7 (P < 0.01), respectively, when compared with control implants. CONCLUSIONS: A single injection of Fst288 at the time of silicone implant insertion into the mice results in a significant reduction in pericapsular inflammation and capsular fibrosis.
format Online
Article
Text
id pubmed-5404443
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54044432017-04-28 Follistatin and the Breast Implant Capsule Frenkiel, Brett A. Temple-Smith, Peter de Kretser, David Southwick, Graeme J. Plast Reconstr Surg Glob Open Experimental BACKGROUND: Breast capsular contracture remains an elusive problem faced by plastic surgeons and is the leading long-term complication after breast implantation. Follistatin (Fst) is a protein with known anti-inflammatory and antifibrotic properties and has the potential to limit the severity of diseases associated with inflammation and fibrosis such as capsular contracture. The aim of this study was to examine the effect of Fst288 on capsular fibrosis around silicone implants in a mouse model. METHODS: BALB/c mice were implanted subcutaneously with untreated silicone implants (baseline control). In the experimental group, immediately after silicone implant insertion, the implant pocket received either a single injection of 1 µg Fst288 or normal saline (internal control). The animals were killed at 3, 5, 7, 14, 28, and 90 days after surgery, and serum, implants, and the surrounding tissue were removed for histological and immunohistochemical analyses. RESULTS: Fst288 treatment resulted in significant decreases in capsule thickness at 28 days (P < 0.05) and 3 months (P < 0.001), decreased collagen production at 14 days (P < 0.05) and 3 months (P < 0.01), decreased angiogenesis at 3 months (P < 0.001), decreased α-smooth muscle actin levels at 3 months (P < 0.05), and a decrease in the number of CD45+ cells at days 5 (P < 0.05) and 7 (P < 0.01), respectively, when compared with control implants. CONCLUSIONS: A single injection of Fst288 at the time of silicone implant insertion into the mice results in a significant reduction in pericapsular inflammation and capsular fibrosis. Wolters Kluwer Health 2017-03-01 /pmc/articles/PMC5404443/ /pubmed/28458972 http://dx.doi.org/10.1097/GOX.0000000000001258 Text en Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Experimental
Frenkiel, Brett A.
Temple-Smith, Peter
de Kretser, David
Southwick, Graeme J.
Follistatin and the Breast Implant Capsule
title Follistatin and the Breast Implant Capsule
title_full Follistatin and the Breast Implant Capsule
title_fullStr Follistatin and the Breast Implant Capsule
title_full_unstemmed Follistatin and the Breast Implant Capsule
title_short Follistatin and the Breast Implant Capsule
title_sort follistatin and the breast implant capsule
topic Experimental
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404443/
https://www.ncbi.nlm.nih.gov/pubmed/28458972
http://dx.doi.org/10.1097/GOX.0000000000001258
work_keys_str_mv AT frenkielbretta follistatinandthebreastimplantcapsule
AT templesmithpeter follistatinandthebreastimplantcapsule
AT dekretserdavid follistatinandthebreastimplantcapsule
AT southwickgraemej follistatinandthebreastimplantcapsule